Wire · opportunities
FDA green lights Priovant drug for rare skin disease
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 28 August 2026 · Fusion42 review
The FDA has approved Lisraya, a drug developed by Priovant, a Roivant subsidiary, for treating a rare skin disease. This marks the first approval of a drug licensed from Pfizer by Priovant, targeting multiple rare inflammatory conditions.
This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it.
◆ ◆ The Wire takeaway
Your biotech startup now faces a slightly altered competitive landscape as a new entrant, Priovant, gains a foothold with a Pfizer-licensed therapy in rare inflammatory skin diseases. This clearance opens a path for partnerships or competition in niche treatment areas.
◆ Coverage
3 sources · 28 Aug 2026
◆ Related on Wire
◆ Topics